Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CLINICAL BENEFITS OF TRAMIPROSATE IN ALZHEIMER’S DISEASE ARE ASSOCIATED WITH HIGHER NUMBER OF APOE4 ALLELES: THE “APOE4 GENE-DOSE EFFECT”

1 Jan 2016

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Dementia and Cognitive Impairment Research
Share to Intracerebral and Subarachnoid Hemorrhage Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29199323
DOI: 10.14283/jpad.2016.115

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CLINICAL BENEFITS OF TRAMIPROSATE IN ALZHEIMER’S DISEASE ARE ASSOCIATED WITH HIGHER NUMBER OF APOE4 ALLELES: THE “APOE4 GENE-DOSE EFFECT”PMID 29199323Read ↗

The APOE genotype: modification of therapeutic responses in Alzheimer's disease.Semantic proximity Read ↗

Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapySemantic proximity Read ↗

Pharmacogenetic Basis for Therapeutic Optimization in Alzheimer’s DiseaseSemantic proximity Read ↗

<i>APOE</i> ε4: The most prevalent yet understudied risk factor for Alzheimer's diseaseSemantic proximity Read ↗

Opportunities in pharmacogenomics for the treatment of Alzheimer’s diseaseSemantic proximity Read ↗

Molecular Insight into the Therapeutic Promise of Targeting APOE4 for Alzheimer's Disease.Semantic proximity Read ↗

APOE genotyping and response to drug treatment in Alzheimer's disease.Semantic proximity Read ↗

Pharmacogenetic Considerations in the Treatment of Alzheimer’s DiseaseSemantic proximity Read ↗

A Quarter Century of APOE and Alzheimer’s Disease: Progress to Date and the Path ForwardSemantic proximity Read ↗

ACE inhibition increases Alzheimer’s disease risk by promoting tau phosphorylationSemantic proximity Read ↗

Influence of pharmacogenetic factors on Alzheimer's disease therapeutics.Semantic proximity Read ↗

Rexinoids as Therapeutics for Alzheimer's Disease: Role of APOESemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.